Rivaroxaban: A review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery

American Journal of Cardiovascular Drugs

Volumn 12, Issue 1, 2012, Pages 57-72

  Duggan, Sean T ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Anticoagulants; Factor Xa inhibitors; Rivaroxaban; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; CARBAMAZEPINE; CLOPIDOGREL; DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYPERICUM EXTRACT; KETOCONAZOLE; LEPIRUDIN; NAPROXEN; PHENYTOIN; RIFAMPICIN; RITONAVIR; RIVAROXABAN; WARFARIN;

ANEMIA; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CAUSE OF DEATH; CHILD CARE; CONSTIPATION; DEEP VEIN THROMBOSIS; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG TOLERABILITY; EXPERIMENTAL ANIMAL; EXPERIMENTAL RABBIT; EXPERIMENTAL RAT; FEVER; GERIATRIC CARE; HUMAN; HYPOTENSION; IN VITRO STUDY; INSOMNIA; INTENTION TO TREAT ANALYSIS; LUNG EMBOLISM; NAUSEA; NONHUMAN; PAIN; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHARMACOECONOMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; POSTOPERATIVE ANEMIA; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; RISK REDUCTION; SINGLE DRUG DOSE; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VOMITING;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; HUMANS; MORPHOLINES; POSTOPERATIVE COMPLICATIONS; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 84856279898     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11208470-000000000-00000     Document Type: Article

References (73)

1. Hyers TM. Management of venous thromboembolism: past, present, and future. Arch Intern Med 2003; 163 (7): 759-68 (Pubitemid 36438047)
2. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008 Jun; 133 (6 Suppl.): 381-453S
3. Deitelzweig SB, Johnson BH, Lin J, et al. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol 2011 Feb; 86 (2): 217-20
4. Dahl OE. Orthopaedic surgery as a model for drug development in thrombosis. Drugs 2004; 64 Suppl 1: 17-25 (Pubitemid 39280366)
5. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125 (1): 1-7
6. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manage Care Pharm 2007 Jul-2007 31; 13 (6): 475-86 (Pubitemid 350193368)
7. Eriksson BI, Quinlan DJ, Weitz JI, et al. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48 (1): 1-22
8. Eriksson BI, Quinlan DJ. Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs 2006; 66 (11): 1411-29
9. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939: an oral, direct factor Xa inhibitor. J Thromb Haemost 2005 Mar; 3 (3): 514-21 (Pubitemid 41632877)
10. Depasse F, Busson J, Mnich J, et al. Effect of BAY 59-7939: a novel, oral direct factor Xa inhibitor on clot-bound factor Xa activity in vitro abstract no. P1104. J Thromb Haemost 2005; 3 (Suppl. 1)
11. Laux V, Perzborn E, Kubitza D, et al. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin Thromb Hemost 2007 Jul; 33 (5): 515-23 (Pubitemid 47105742)
12. Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-4-(3-oxomorpholin-4-yl) phenyl-1, 3-ox-azolidin-5-yl} methyl) thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005 Sep 22; 48 (19): 5900-8 (Pubitemid 41324601)
13. Bayer Schering Pharma. Xarelto® (rivaroxaban 10 mg tablets): EU summary of product characteristics online. Available from URL: http://www.medicines. org.uk/emc/document.aspx?documentId=21265 Accessed 2012 Jan 11
14. Perzborn E, Lange U. Rivaroxaban: an oral, direct factor Xa inhibitor inhibits tissue factor-mediated platelet aggregation abstract no. P-W-642. J Thromb Haemost 2007; 5 (Suppl. 2)
15. Wong PC, Crain E, Watson C, et al. Comparative antithrombotic and antihemostatic effects of the direct factor Xa inhibitors, apixaban and rivaroxaban, and the direct thrombin inhibitors, dabigatran and lepirudin, in rabbit models of venous thrombosis and bleeding time abstract no. 3025. 50th American Society of Hematology Annual Meeting and Exposition; 2008 Dec 6-9; San Francisco (CA)
16. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005 Oct; 78 (4): 412-21 (Pubitemid 41393676)
17. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005 Dec; 61 (12): 873-80 (Pubitemid 41803696)
18. Mueck W, Becka M, Kubitza D, et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther 2007 Jun; 45 (6): 335-44 (Pubitemid 46895052)
19. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once-and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008 Sep; 100 (3): 453-61
20. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008; 47 (3): 203-16
21. Graff J, von Hentig N, Misselwitz F, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and pro-thrombinase activity. J Clin Pharmacol 2007 Nov; 47 (11): 1398-407 (Pubitemid 47624591)
22. Gerotziafas GT, Elalamy I, Depasse F, et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban letter. J Thromb Haemost 2007 Apr; 5 (4): 886-8 (Pubitemid 46563600)
23. Walenga JM, Prechel M, Jeske WP, et al. Rivaroxaban-an oral, direct factor Xa inhibitor-has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol 2008 Jul 30; 143: 92-9
24. Kubitza D, Becka M, Mueck W, et al. Rivaroxaban (BAY 59-7939)-an oral, direct factor Xa inhibitor-has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2007 Apr; 63 (4): 469-76 (Pubitemid 46426627)
25. Kubitza D, Becka M, Mueck W, et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct factor Xa inhibitor-are not affected by aspirin. J Clin Pharmacol 2006 Sep; 46 (9): 981-90 (Pubitemid 44215062)
26. Kubitza D, Becka M, Mueck W, et al. Co-administration of rivaroxaban-a novel, oral, direct factor Xa inhibitor-and clopidogrel in healthy subjects abstract no. 1272. Eur Heart J 2007 Sep; 28 (Abstr. Suppl.): 189
27. Kubitza D, Mueck W, Becka M. Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf 2008; 31 (1): 67-77
28. Jiang J, Hu Y, Zhang J, et al. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban-an oral, direct factor Xa inhibitor-in elderly Chinese subjects. Thromb Haemost 2010; 103 (1): 234-41
29. Zhao X, Sun P, Zhou Y, et al. Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct factor Xa inhibitor rivaroxaban in healthy Chinese subjects. Br J Clin Pharmacol 2009; 68 (1): 77-88
30. Kubitza D, Becka M, Zuehlsdorf M, et al. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007 Feb; 47 (2): 218-26 (Pubitemid 46146488)
31. Kubitza D, Becka M, Zuehlsdorf M, et al. Effects of single-dose BAY 59-7939-an oral, direct factor Xa inhibitor-in subjects with extreme body weight abstract no. 1872. Blood 2005 Nov 16; 106 (11): 532
32. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol 2010 Nov; 70 (5): 703-12
33. Kubitza D, Becka M, Mueck W, et al. The effect of age and gender on the pharmacology and safety of the oral, direct factor Xa inhibitor rivaroxaban abstract no. P-T-628. 21st Congress of the International Society on Thrombosis and Haemostasis; 2007 Jul 6-12; Geneva
34. Kubitza D, Becka M, Mueck W, et al. The effect of extreme age, and gender on the pharmacology and tolerability of rivaroxaban: an oral, direct factor Xa inhibitor. Blood 2006; 108 (11): 271-2
35. Janssen Pharmaceuticals Inc. Prescribing Information: xarelto (rivaroxaban) online. Available from URL: http://www.janssenpharmaceuticalsinc. com/assets/xareltopi.pdf Accessed 2012 Jan 11
36. Center for Drug Evaluation and Research. Medical review of rivaroxaban (xar-eltoTM) online. Available from URL: http://www.accessdata.fda.gov/drug satfda-docs/nda/2011/022406Orig1s000MedR.pdf Accessed 2011 Oct 25
37. Bayer Inc. Xarelto® (rivaroxaban 10 mg tablets): product monograph online. Available from URL: http://www.bayer.ca/files/XARELTO-PM-ENG-14SEP2011- 142438.pdf?# Accessed 2012 Jan 11
38. Kubitza D, Becka M, Zuehlsdorf M, et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006 May; 46 (5): 549-58
39. Moore TK, Plotinov AN, Thyssen A, et al. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban. J Cardiovasc Pharmacol 2011. Epub
40. Lang D, Freudenberger C, Weinz C. In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans. Drug Metab Dispos 2009 Feb 5; 37 (5): 1046-55
41. Weinz C, Schwarz T, Kubitza D, et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009 Feb 5; 37 (5): 1056-64
42. Eriksson BI, Borris L, Dahl OE, et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006 Jan; 4 (1): 121-8
43. Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006 Nov 28; 114 (22): 2374-81 (Pubitemid 44847454)
44. Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005 Nov; 3 (11): 2479-86 (Pubitemid 41727165)
45. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008 Jun 26; 358 (26): 2765-75 (Pubitemid 351930851)
46. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008 Jun 26; 358 (26): 2776-86 (Pubitemid 351930852)
47. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. Lancet 2009 May 16; 373 (9676): 1673-80
48. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008 Jul 5; 372 (9632): 31-9
49. Eriksson BI, Kakkar AK, Turpie AG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 2009 May; 91 (5): 636-44
50. Eriksson BI, Turpie AG, Lassen MR, et al. A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopaedic surgery: effects of specified co-medications abstract no. 1986. 50th American Society of Hematology Annual Meeting and Exposition; 2008 Dec 6-9; San Fransisco (CA)
51. Turpie AG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies. Thromb Haemost 2011 Mar; 105 (3): 444-53
52. Diamantopoulos A, Lees M, Wells PS, et al. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembo-lism in Canada. Thromb Haemost 2010 Oct; 104 (4): 760-70
53. Duran A, Sengupta N, Diamantopoulos A, et al. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payers perspective. J Med Econ 2011; 14 (6): 824-34
54. Nicolaides AN, Fareed J, Kakkar AK. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006 Jun; 25 (2): 101-61 (Pubitemid 44043713)
55. Wells PS, Borah BJ, Sengupta N, et al. Analysisof venousthromboprophylaxis duration and outcomes in orthopedic patients. Am J Manag Care 2010 Nov; 16 (11): 857-63
56. Qadan M, Polk HC Jr, Hohmann SF, et al. A reassessment of needs and practice patterns in pharmacologic prophylaxis of venous thromboembolism following elective major surgery. Ann Surg 2011 Feb; 253 (2): 215-20
57. Reynolds NA, Perry CM, Scott LJ. Fondaparinux sodium: areviewof its use in the prevention of venous thromboembolism following major orthopaedic surgery. Drugs 2004; 64 (14): 1575-96 (Pubitemid 38981840)
58. Mori S, Matsuura A, Rama Prasad YV, et al. Studies on the intestinal absorption of low molecular weight heparin using saturated fatty acids and their derivatives as an absorption enhancer in rats. Biol Pharm Bull 2004 Mar; 27 (3): 418-21 (Pubitemid 41685491)
59. Samama MM, Gerotziafas GT. Newer anticoagulants in 2009. J Thromb Thrombolysis 2010 Jan; 29 (1): 92-104
60. European Medicines Agency (EMEA). European public assessment report. Pradaxa online. Available from URL: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Public-assessment-report/human/000829/WC500041062.pdf Accessed 2012 Jan 11
61. Boehringer Ingelheim Canada Ltd. PradaxTM (dabigatran etexilate capsules 75mg and 110 mg): product monograph online. Available from URL: http://www.boehringer-ingelheim.ca/content/dam/internet/opu/ca-EN/doc uments/humanhealth/product-monograph/Pradax-pm.pdf Accessed 2012 Jan 11
62. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Published erratum appears in Lancet 2007 Dec 15; 370 (9604): 2004. Lancet 2007 Sep 15; 370 (9591): 949-56 (Pubitemid 47393577)
63. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. Journal of Thrombosis & Haemostasis 2007 Nov; 5 (11): 2178-85 (Pubitemid 47617868)
64. RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009 Jan; 24 (1): 1-9
65. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008 Mar; 28 (3): 380-6
66. Carter NJ, McCormack PL, Plosker GL. Enoxaparin: a review of its use in ST-segment elevation myocardial infarction. Drugs 2008; 68 (5): 691-710 (Pubitemid 351451548)
67. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011. Epub
68. Fareed J, Ma Q, Florian M, et al. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis. Semin Thromb Hemost 2004 Feb; 30 Suppl 1: 89-104 (Pubitemid 38453587)
69. Diamantopoulos A, LeReun C, Rasul F, et al. Indirect comparisons of rivaroxaban vs alternative prophylaxis for the prevention of venous throm-boembolism in patients undergoing total hip or total knee replacement abstract no. 1292. 50th American Society of Hematology Annual Meeting and Exposition; 2008 Dec 6-9; San Fransisco (CA)
70. Lereun C, Wells P, Diamantopoulos A, et al. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. J Med Econ 2011; 14 (2): 238-44
71. Loke YK, Kwok CS. Dabigatran and rivaroxaban for prevention of venous thromboembolism: systematic review and adjusted indirect comparison. J Clin Pharm Ther 2011 Feb; 36 (1): 111-24
72. Trkulja V, Kolundzic R. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. Croat Med J 2010 Apr 15; 51 (2): 113-23
73. Bayer. Xarelto regulatory post-marketing surveillance ClinicalTrials.gov identifier NCT01029743. US National Institutes of Health, Clinical Trials. gov online. Available from URL: http://www.clinicaltrials.gov Accessed 2012 Jan 11